Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.50 |
| ▸ | MMP1 | P03956 | 4/20 | 0.50 |
| ▸ | MMP3 | P08254 | 4/20 | 0.50 |
| ▸ | CETP | P11597 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359365 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL1358861 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL29893945 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL1359364 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL1358863 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL1358859 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| SCHEMBL1358862 | 1.00 | MMP2 (0.50) | MMP2MMP1MMP3CETPCNR2 | |
| Hydrochloric Acid SCHEMBL2679110 | 0.99 | MMP2 (0.49) | MMP2MMP1MMP3CETP | |
| Hydrochloric Acid SCHEMBL2679113 | 0.99 | MMP2 (0.49) | MMP2MMP1MMP3CETP | |
| SCHEMBL30873579 | 0.99 | MMP2 (0.48) | MMP2MMP1MMP3CETPCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | claimed |
| US-20230227489-A1 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | CRODA INTERNATIONAL PLC (GB) | 2023-07-20 | — | — | US | disclosed |
| EP-3440179-A2 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | Croda International PLC (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174748-A2 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | CRODA INTERNATIONAL PLC (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227489-A1 | GLYCOLIPOPEPTIDE BIOSURFACTANTS | LYPLAL1, LNPEP, PHOSPHO1 | MMP2 1888/4885MMP1 2947/4885MMP3 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.